Janus Henderson Group PLC Larimar Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

$174 Billion
Q1 2025

A detailed history of Janus Henderson Group PLC transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 5,571,963 shares of LRMR stock, worth $18.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

5,571,963

Previous 6,443,286 13.52%

Holding current value

$18.5 Million

Previous $24.6 Million 51.33%

% of portfolio

0.01%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$2.15 - $4.18 $1.87 Million - $3.64 Million	-871,323 Reduced 13.52%	5,571,963 $12 Million
Q4 2024 Feb 14, 2025	BUY	$3.8 - $9.29 $3.33 Million - $8.14 Million	876,431 Added 15.74%	6,443,286 $24.6 Million
Q3 2024 Nov 14, 2024	BUY	$6.3 - $10.68 $7.49 Million - $12.7 Million	1,189,467 Added 27.17%	5,566,855 $36.5 Million
Q2 2024 Aug 14, 2024	BUY	$6.33 - $9.89 $2.26 Million - $3.53 Million	356,423 Added 8.86%	4,377,388 $31.7 Million
Q1 2024 May 15, 2024	BUY	$4.2 - $13.28 $5.8 Million - $18.3 Million	1,379,900 Added 52.25%	4,020,965 $30.5 Million
Q4 2023 Feb 14, 2024	BUY	$2.35 - $4.71 $422,067 - $845,930	179,603 Added 7.3%	2,641,065 $12 Million
Q3 2023 Nov 14, 2023	BUY	$3.08 - $4.49 $3.13 Million - $4.56 Million	1,015,736 Added 70.26%	2,461,462 $9.72 Million
Q2 2023 Aug 14, 2023	BUY	$3.13 - $5.27 $1.17 Million - $1.98 Million	375,295 Added 35.06%	1,445,726 $4.53 Million
Q1 2023 May 15, 2023	BUY	$4.0 - $6.68 $572,648 - $956,322	143,162 Added 15.44%	1,070,431 $4.85 Million
Q4 2022 Feb 14, 2023	BUY	$2.73 - $5.08 $347,444 - $646,526	127,269 Added 15.91%	927,269 $3.83 Million
Q3 2022 Nov 14, 2022	BUY	$1.53 - $3.64 $77,925 - $185,392	50,932 Added 6.8%	800,000 $2.57 Million
Q2 2022 Aug 15, 2022	SELL	$1.9 - $3.98 $562,736 - $1.18 Million	-296,177 Reduced 28.34%	749,068 $1.48 Million
Q1 2022 May 16, 2022	BUY	$3.65 - $10.84 $1.13 Million - $3.36 Million	310,133 Added 42.19%	1,045,245 $4.22 Million
Q4 2021 Feb 14, 2022	BUY	$8.86 - $13.47 $832,813 - $1.27 Million	93,997 Added 14.66%	735,112 $7.92 Million
Q3 2021 Nov 16, 2021	BUY	$9.61 - $15.11 $385,889 - $606,742	40,155 Added 6.68%	641,115 $7.46 Million
Q2 2021 Aug 16, 2021	BUY	$8.0 - $15.2 $3.67 Million - $6.97 Million	458,613 Added 322.18%	600,960 $5.89 Million
Q1 2021 May 17, 2021	BUY	$14.61 - $22.19 $52,625 - $79,928	3,602 Added 2.6%	142,347 $2.08 Million
Q4 2020 Feb 16, 2021	SELL	$14.28 - $25.06 $354,915 - $622,841	-24,854 Reduced 15.19%	138,745 $2.97 Million
Q3 2020 Nov 16, 2020	BUY	$10.5 - $17.6 $1.72 Million - $2.88 Million	163,599 New	163,599 $2.54 Million

Others Institutions Holding LRMR

# of Institutions

114

Shares Held

64.6M

Call Options Held

93.5K

Put Options Held

68K

View Full List

About Larimar Therapeutics, Inc.

Ticker LRMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,269,200
Market Cap $144M
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...

More about LRMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Larimar Therapeutics, Inc. Transaction History